Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours

被引：0
作者：
Caponigro F. [1 ]
Avallone A. [1 ]
Rivellini F. [1 ]
Comella P. [1 ]
Ionna F. [2 ]
De Rosa V. [2 ]
Comella G. [1 ]
机构：
[1] Division of Medical Oncology A, National Tumor Institute, 80131 Naples, Via Mariano Semmola
[2] Division of Head and Neck Surgery, National Tumor Institute "G. Pascale", 80131 Naples, Via Mariano Semmola
来源：
Cancer Chemotherapy and Pharmacology | 2001年 / 47卷 / 2期
关键词：
5-Fluorouracil; Advanced solid tumours; Levofolinic acid; Mitoxantrone; Raltitrexed;
D O I：
10.1007/s002800000194
中图分类号：
学科分类号：
摘要：
Purpose: We have recently evaluated the combination of raltitrexed, levofolinic acid (LFA) and 5-fluorouracil (5-FU) in advanced head and neck and colorectal cancer, and we have shown that this combination is well tolerated and has clinical activity. Clinical combination studies have shown that raltitrexed and anthracyclines can be combined at full doses without unexpected toxicities. Based on these observations, we started a phase I study of mitoxantrone plus raltitrexed administered on day 1, followed by LFA and 5-FU on day 2 in patients with advanced solid tumors. Patients and methods: Mitoxantrone was given at a starting dose of 6 mg/m2, raltitrexed at a fixed dose of 3 mg/m2, LFA at a fixed dose of 250 mg/m2, and 5-FU at a starting dose of 750 mg/m2. Mitoxantrone and 5-FU doses were subsequently escalated alternately up to dose-limiting toxicity. Treatment was repeated every 14 days. Results: Four dose levels were tested in 18 patients. All three patients treated at the fourth dose level had grade 4 neutropenia after the first cycle. Therefore, this level was defined as the maximum tolerated dose and the dose level immediately, below (mitoxantrone 7 mg/m2 and 5-FU 900 mg/m2) was selected for further evaluation. Neutropenia was the main toxic effect. Nonhaematologic side effects were mild. One complete response and five partial responses (all but one in patients with head and neck cancer) were observed, for an overall response rate of 33% (95% confidence interval, 13% to 59%). Conclusions: Mitoxantrone, raltitrexed and 5-FU can be combined at doses which are close to those used in monotherapy. The observed activity is encouraging, especially in the subset of patients with head and neck cancer.
引用
收藏
页码：113 / 116
页数：3
相关论文
共 9 条
  • [1] Budillon A., Barbarulo D., Di Gennaro E., Manzo C., Comella G., Caponigro F., In vitro cytotoxicity of Tomudex (TOM) in combination with 5-fluorouracil (5-FU) and levofolinic acid (LFA) in head and neck and colon cancer cell lines, Ann Oncol, 9, (1998)
  • [2] Caponigro F., Avallone A., McLeod H.L., Carteni G., De Vita F., Casaretti R., Morsman J., Blackie R., Budillon A., De Lucia L., Gravina A., Catalano G., Comella P., Comella G., Phase I and pharmacokinetic study of Tomudex combined with 5-fluorouracil + levofolinic acid in advanced head and neck and colorectal cancer, Clin Cancer Res, 5, pp. 3948-3955, (1999)
  • [3] Cunningham D., Zalcberg J., Smith I., Gore M., Pazdur R., Burris H., Meropol N.J., Kennealey G., Seymour L., Tomudex (ZD 1694): A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours, Ann Oncol, 7, pp. 179-182, (1996)
  • [4] Gebbia V., Testa A., Valenza R., Zerillo G., Restivo S., Cupido G., A phase II study of levofolinic acid and fluorouracil plus cisplatin in patients with advanced head and neck carcinoma, Oncology, 50, pp. 490-494, (1993)
  • [5] Henderson I.C., Allegra J.C., Woodcock T., Wolff S., Bryan S., Cartwright K., Dukart G., Henry D., Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer, J Clin Oncol, 7, pp. 560-571, (1989)
  • [6] Longo G.S.A., Izzo J., Chang Y.M., Tong W.P., Zielinski Z., Garlick R., Chan T.C., Bertino J.R., Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity, Clin Cancer Res, 4, pp. 469-473, (1998)
  • [7] Soukop M., Eatock M.M., Anthoney D.A., El-Abassi M., Wilson P., Paul J., Smith M., Evans T.R.J., Final results of a dose finding study of raltitrexed (Tomudex) with cisplatin and epirubicin as first line therapy for metastatic or unresectable gastric and oesophageal adenocarcinoma, Proc Am Soc Clin Oncol, 18, (1999)
  • [8] Ten Bokkel Huinink D., Batenburg de Jong R.J., Verschuur H.P., Keizer H.J., A phase I/II study of tomudex and cisplatin in the treatment of patients with locally advanced or metastatic head and neck cancer, Proc Am Soc Clin Oncol, 18, (1999)
  • [9] Wong R.P., Bjarnason G., Charpentier D., Winquist E., Abugaber A., Matthews S., Raltitrexed (Tomudex) plus doxorubicin (DOX) in patients with advanced cancer: Results of a phase I dose escalation study, Proc Am Soc Clin Oncol, 18, (1999)
1